ChemicalBook
English
1418200-58-4Sofituzumab Vedotin
1690318-25-2Crizanlizumab
1218540-53-42-Amino-N1-[1-(3-pyridyl)ethyl]succinamide
1807960-57-1Lesofavumab
2093956-19-3帕洛利单抗
2173054-79-8ASTEGOLIMAB (艾特利单抗 )
2135632-36-7MAFTIVIMAB (玛替韦单抗 )
1807546-55-9cis-2-(Boc-amino)cyclopropylboronic Acid Pinacol Ester
1792982-57-0Cosfroviximab
1246264-45-8Bezlotoxumab
1202526-59-7帕替组单抗
2408957-56-01-Amino-5-bromo-2,2-dimethylindane
1234137-51-9IFABOTUZUMAB
1969309-56-5Zenocutuzumab
1448221-67-7Emactuzumab
946415-62-9Ontuxizumab
1055306-64-31-Boc-3,3-difluoro-4-methylenepyrrolidin-2-one
1314895-84-55-Aminopiperidin-3-ol
1667717-41-0GBT 440 hydrochloride
371919-42-5(S)-1-[(S)-2-Amino-3,3-dimethylbutanoyl]-N-(4-iodophenyl)-N-phenylpyrrolidine-2-carboxamide
1528523-94-5德屈库单抗
934235-44-6ROBATUMUMAB ( 罗妥木单抗 )
1476039-58-3奈莫利珠单抗
1989556-22-0Nirsevimab
1518996-49-0Andecaliximab
4530-45-43-(Dichloromethyl)phenyl Acetate
1969313-51-6奥瓦利单抗
946415-64-1FORALUMAB ( 福雷芦单抗 )
1310460-86-6Modotuximab
1026559-41-05-Chloropyridin-3-yl 1H-Indole-5-carboxylate
1902219-82-2Methyl (2R,3R)-rel-3-Aminobicyclo[2.2.1]hept-5-ene-2-carboxylate
30435-35-92-Chloro-4-methyl-6-nitroanisole
915404-94-3CARLUMAB ( 卡芦单抗 )
2287286-00-21-(Chloromethyl)-3-(4-fluorophenyl)bicyclo[1.1.1]pentane
1582205-90-0厄瑞努单抗
1884201-71-1Mirikizumab
2245084-47-1tert-Butyl 5,6,7-Trifluoro-1-oxo-1,3-dihydrospiro[indene-2,4’-piperidine]-1’-carboxylate
339086-79-2ROVELIZUMAB ( 罗维珠单抗 )
1356963-03-51-(4-Amino-5-methoxy-2-methylphenyl)-N,N-dimethylpiperidin-4-amine
1206681-39-1NAMILUMAB ( 那美芦单抗 )
1535963-91-7萨特利珠单抗
2136633-23-1DISITAMAB VEDOTIN (纬迪西妥单抗 )
854396-49-93-Iodo-2-nitrodibenzo[b,d]furan
2052591-32-7Samrotamab
1791411-57-8Lutikizumab
1708936-80-4夫卢维单抗
1824663-83-3Sirtratumab Vedotin
1241914-79-32,2-Difluoro-2-(4-fluorophenyl)acetyl Chloride
2229685-51-0艾维奇单抗
918127-53-4TIGATUZUMAB ( 替加组单抗 )
87920-07-82-(2-Methyl-1,3-dioxolan-2-yl)-1-phenylethanone
1613144-80-1Cabiralizumab
1227664-20-12-(Methoxycarbonyl)indole-3-boronic Acid Pinacol Ester
948564-73-6非苏木单抗
114665-49-58-Amino-5,6,7,8-tetrahydronaphthalen-1-ol
1393641-34-3替西木单抗
1401812-88-1Lifastuzumab Vedotin
1331830-76-2培拉凯珠单抗
1807809-74-04-[4-(2-Fluoroethyl)-1-piperazinyl]-2-methoxyaniline
1351470-17-1Setoxaximab
1648796-29-5瑾司鲁单抗
1043556-46-2更汀芦单抗
1345009-45-1万替妥单抗
2019133-28-7泽格特奈单抗
1607793-29-2法瑞西单抗
1259366-27-2Methyl (2R,3R)-rel-3-Aminobicyclo[2.2.1]heptane-2-carboxylate
2055640-86-1Mitazalimab
1781223-80-0Telisotuzumab
1073538-99-4Timolumab
1186098-83-8OXELUMAB ( 奥塞芦单抗 )
1204390-13-5Dusigitumab
1806849-64-85-Bromo-6-fluoropicolinonitrile
1182724-82-87-Bromodibenzo[f,h]quinoxaline
1879918-31-6Loncastuximab Tesirine
2056878-75-0Osocimab
1685249-67-5Losatuxizumab Vedotin
2043952-59-4阿泽奇单抗
1801544-27-3Losatuxizumab
1446419-85-7Evinacumab
1784576-75-52-Methoxycyclopropanecarbaldehyde
2052649-42-8Samrotamab Vedotin
1256258-86-2Inclacumab
1939109-24-6Berlimatoxumab
2094516-02-4CINPANEMAB (辛帕奈单抗 )
953400-68-5来瑞组单抗
823788-82-5HuCC49
1350624-75-7玛格妥昔单抗
2148334-68-1TAMRINTAMAB PAMOZIRINE (帕他林妥单抗 )
921618-45-3卡利尤单抗
2171765-46-92-(Fmoc-amino)-3-mercapto-3-methylbutanoic Acid
1227623-09-71,8-Naphthyridine-2-boronic Acid
7377-53-9CAPRYLOHYDROXAMIC ACID
2044984-83-8艾替利单抗
1156467-77-46-Bromo-3-oxoindane-5-carbonitrile
1094438-61-55-Bromo-2-ethoxybenzyl Bromide
103307-09-12,3-diphenyldibenzoquinoxaline
2135632-29-8ATOLTIVIMAB (阿替韦单抗 )
1791420-09-1Dilpacimab
748817-16-5N-(10-Aminodecyl)-5-[(3aS,4S,6aR)-2-oxohexahydro-4-thieno[3,4-d]imidazolyl]pentanamide 2,2,2-Trifluoroacetate
1831098-91-9Duvortuxizumab
3140 3141 3142 3143 3144 3145 3146 3147 3148 3149 3150 3151 3152 3153 3154 3155 3156 3157 3158 3159 3160 3161 3162 3163 3164 3165 3166 3167 3168 3169 3170 3171 3172 3173 3174 3175 3176 3177 3178 3179 3180 3181 3182 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 3194 3195 3196 3197 3198 3199 3200 3201 3202 3203 3204 3205 3206 3207 3208 3209 3210 3211 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 3243 3244
Copyright 2019 © ChemicalBook. All rights reserved